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Abstract
Background: AMH levels determined by the conventional AMH assay declined during pregnancy and postpartum.
A new Beckman Coulter AMH Gen II assay removes the potentially assay-interfering complement which is activated
in pregnancy. The aim of this study was to evaluate if the decline of AMH levels in the serum of pregnant women
during the course of pregnancy and peripartum was assay-dependent and thus artificial.
Methods: In this cross-sectional study prepartal blood samples were collected from 62 patients (median age
30.6 years [interquartile range: 25.6 - 34.5]) in the third trimester of pregnancy and again 1–4 days after delivery
between 2011 and 2012. In another cohort of 11 patients (median age 34.1 years [interquartile range: 32.6 - 37.8])
blood samples were taken in different trimesters of pregnancy between 1995 and 2001. The conventional and the
modified AMH assay were performed in the same patient serum samples. We used the conventional and the
modified AMH-Gen-II ELISA (Beckman Coulter, Immunotech, Webster, USA) for the assessment of AMH levels. The
Wilcoxon signed rank test was used for determining differences between AMH levels pre- and postpartum. The
method of Bland and Altman was applied for analyzing the agreement of both methods for determining AMH
levels.
Results: AMH values peripartum were lower than those expected in fertile non-pregnant women of comparable
age. An overall mean difference of 0.44 ng/ml was observed between the conventional and the modified assay.
Measurements with the modified assay showed a significant decline of postpartal levels compared with prepartal
levels which is consistent with values obtained using the conventional assay (both p < 0.00001). Compared to the
longitudinal measurements of AMH levels determined using the conventional assay, AMH levels obtained using the
modified assay suggest a steeper decline of values during the course of pregnancy.
Conclusion: By comparing the conventional assay for AMH determination with the modified assay the present
study confirmed that AMH levels decline during the course of pregnancy and early after delivery.
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Background
Anti-Mullerian Hormone (AMH) is known to be the most
precise predictor of ovarian reserve in women [1, 2]. It is
produced by the granulosa cells of small antral and pre-
antral follicles and reflects the size of the pool of these folli-
cles [3, 4]. AMH declines with age [5] but remains stable
during the menstrual cycle [6, 7] allowing its determination
at random [8]. We have recently observed that AMH de-
creases during pregnancy, showing the lowest values peri-
partum, followed by a significant increase of AMH during
the first four days after delivery [9]. We concluded that the
extremely hypogonadotropic status in pregnancy could be
responsible for the decline of AMH during pregnancy,
followed by a rapid recovery after delivery. In the respective
study, we used the Beckman Coulter Gen II Assay which
was available until July 2013. Recent studies have suggested
that storage conditions led to fluctuations of AMH values
determined by this assay, whereas a modified AMH Beck-
man Coulter Gen II Assay (available since July 2013) re-
sulted in more stable values of AMH independent of
storage time and conditions [10, 11]. Additionally, the
AMH levels determined by the modified assay are reported
to be higher [11]. According to the manufacturer, this effect
may reflect a possible interaction of complement with the
conventional assay resulting in fluctuations due to individ-
ual complement activation during storage. The modified
assay includes a pre-mixing step with a highly anionic buf-
fer which removes this complement.
It is thought that pregnancy is associated with comple-
ment activation [12–15] that may lead to a more pro-
nounced difference of AMH determined by the
conventional assay compared to the modified assay in
pregnant women as a result of sample handling and stor-
ing conditions [11]. According to these observations, de-
creased AMH levels peripartally may simply be an
artificial phenomenon.
In the present study we have determined AMH levels
during pregnancy and peripartum with the new modified
AMH assay in a subgroup of our study population in
which the conventional assay was recently used to deter-
mine AMH values [9]. The aim was to explore whether
the low prepartal levels of AMH may have been assay-
dependent and artificial due to progressive complement
activation in the course of pregnancy.
Methods
Study population
Prepartal blood samples were collected from 62 patients
aged between 18 to 41 years (median age 30.6 years
[interquartile range (IQR): 25.6 - 34.5]) in the third tri-
mester of pregnancy as the patients presented for labour
and again 1–4 days after delivery. None of the patients
included in this study exhibited a history of infertility,
operations on the ovaries, chemotherapy or radiation in
the past. All women were examined between 2011 and
2012. Informed written consent was obtained from all
women and the study was approved by the local research
ethics committee (number 11–4643).
Blood samples were taken between October 10th, 2011
and February 21th, 2012. The conventional assay was
used in frozen samples between November 9th, 2011 and
February 27th, 2012. The modified assay was performed
using frozen aliquots of the same patient samples on July
18th, 2014.
In another cohort of 11 patients aged between 29 to
39 years (median age 34.1 years [IQR: 32.6 - 37.8]) who
presented in our clinic between 1995 and 2001, we took
blood samples during various trimesters of pregnancy
and evaluated AMH levels at several points during the
course of the pregnancy.
The determination of values with the conventional assay
took place between December 6th, 2011 and February
12th, 2012. The determination of values with the modified
assay took place on August 8th, 2014.
All patients included in the present study were part of
the study populations used for our recently published
study [9]. Aliquots from identical blood samples were
used for both studies. As no additional aliquots were avail-
able for some participants of the original study population,
only 62 out of the original 69 and 11 out of the original 15
patients were included in the present study. No substantial
differences in AMH levels (assessed using the conven-
tional assay) were detected between the original study
population and the subgroup included in the present
study.
Sampling of blood serum
Blood samples (9 ml) were collected from each woman
using S-Monovettes (Sarstedt AG & Co.), immediately
stored at 4 °C and processed within 4 h to avoid blood
cell lysis. Blood fractionation was carried out by centrifu-
gation for 10 min at 2500xg. Subsequently, 3 to 4 ml of
the upper phase constituting blood serum were removed
for the assessment of AMH levels. Samples were pipet-
ted into 4 aliquots and stored at −80 °C.
Determination of AMH levels with the conventional assay
As previously stated [9], we first used the enzymatically
amplified two-site AMH-Gen-II ELISA (Beckman
Coulter, Immunotech, Webster, Texas, USA) which was
available until July 2013. Undiluted serum samples and
controls were dispensed into the wells which were
coated with anti-AMH antibody, followed by the
addition of the anti-AMH detection antibody labelled
with biotin. 100 μl of the streptavidin-horseradish perox-
idase (HRP) was added after washing, followed by the
addition of 100 μl of substrate solution containing TMB
for 8–12 min. Using an automatic ELISA reader (Bio-
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Rad, Hercules, CA) the degree of enzymatic turnover of
the substrate was determined by dual wavelength ab-
sorbance measurement at 450 nm and between 600 and
630 nm. The absorbance measured was directly propor-
tional to the AMH concentration in the samples which
was calculated from the calibration curve. The results
were expressed in ng/ml. Concentrations below 0.08 ng/
ml were considered undetectable.
Determination of AMH levels with the modified assay
The revised test procedure includes an additional assay
step before adding AMH Gen II Calibrators, controls, or
AMH samples to the microplate. This additional step
eliminates the complement interference.
Before adding a sample to the AMH Gen II ELISA mi-
croplate, all calibrators, controls, and samples were pre-
pared with the AMH Gen II Assay Buffer (A56021) as
follows. In a sample tube, 1 part of each calibrator, con-
trol, or test sample respectively was thoroughly mixed
with 5 parts AMH Gen II Assay Buffer (for example,
60 μL calibrator, control, or sample + 300 μL AMH Gen
II Assay Buffer). No dilution factor was required. Within
one hour, 120 μL of the premixed calibrators, controls
and samples were added to the appropriate wells and the
test proceeded like the conventional AMH Gen II assay.
Statistical analysis
AMH levels were found not to be normally distributed
in the study populations (based on visual inspection and
Shapiro-Wilks test; p < 0.0001). Thus, results are re-
ported as median and interquartile ranges. Differences
between AMH levels pre- and postpartum were analyzed
using the Wilcoxon signed rank test with the level of
statistical significance set at α = 0.05. Agreement of
methods for determining AMH levels was analyzed
using the method of Bland and Altman [16]. Statistical
analyses and boxplots were performed using the R statis-
tical package version 3.0.2 [17]. All other plots were cre-
ated by using SPSS version 20 [18].
Results
AMH levels pre- and postpartum
Compared to the conventional assay, measurement of AMH
values with themodified assay resulted in higher values with a
median level of 1.04 ng/ml (IQR: 0.40 – 1.87) prepartal and
0.77 ng/ml (IQR: 0.31 – 1.52) postpartal (Table 1). Measure-
ments with the modified assay showed a significant decline of
postpartal levels compared to prepartal levels which is
consistent with values obtained using the conventional assay
(both p < 0.00001) (Fig. 1,Table 1).
Agreement of methods
Figure 2 shows scatter plots including linear regression lines
and lines of equality as well as the results of the Bland-
Altman analyses including mean differences and 95 % limits
of agreement between both methods. An overall mean dif-
ference of 0.44 ng/ml is observed between the conventional
and the modified assay (Fig. 2a) when pre- and postpartal
AMH measurements are combined. The results suggest
that differences between both assays increase with rising
AMH values irrespective of whether AMH was assessed
pre- or postpartally. This is also reflected by the lower mean
difference and the smaller limits of agreement observed for
postpartal AMH levels compared to prepartal, as postpartal
AMH levels were on average lower than those measured
prepartal (Fig. 2b and c).
AMH levels during the course of pregnancy
Compared to the longitudinal measurements of AMH
levels determined using the conventional assay (Fig. 3a)
graphical analysis of AMH levels determined using the
modified assay suggests a steeper decline of values dur-
ing the course of pregnancy (Fig. 3b).
Discussion
The aim of this study was to investigate whether decreas-
ing prepartal levels of AMH reported previously may have
been assay-dependent and thus artificial. As recently re-
ported by us [9] AMH levels declined with ongoing gesta-
tional age until the first day postpartum. This decline was
questioned as being artificial, since to the development of
a modified assay, available since July 2013, eliminated the
complement and resulted in less storage-dependent AMH
fluctuations as well as consistently higher AMH values. It
was supposed that a serological factor like complement
was able to interfere with the conventional assay and indi-
vidual complement activation resulted in fluctuations,
whereas no consistent fluctuation patterns were described
with the modified assay [11]. According to the manufac-
turer’s instructions, the consistently higher values deter-
mined with the modified assay were attributable to a step
during the assay procedure whereby the effects of comple-
ment were eliminated. Since complement is activated in
pregnancy, the decline described in our recently published
study could be considered as artificial due to the comple-
ment binding action of the assay.
Table 1 AMH values determined with the conventional and the modified assay (Median and IQR)
N = 62 AMH prepartal in ng/ml AMH postpartal in ng/ml p-value
conventional assay 0.59 (0.22 – 1.13) 0.44 (0.18 – 0.91) <0.00001
modified assay 1.04 (0.40 – 1.87) 0.77 (0.31 – 1.52) <0.00001
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As shown by us, AMH values determined using the con-
ventional as well as the modified assay seem to decline in
the course of pregnancy and peripartum. Peripartal AMH
values were lower than those expected in fertile non-
pregnant women of comparable age [5]. The determination
at the end of the third trimester resulted in very low values
with both assays, reflecting the gestational age associated
decline. The ongoing decline early after delivery was
Fig. 1 a: Box plots illustrating the distribution of AMH levels in women with AMH measurements prepartum and postpartum assessed using the
enzymatically amplified two-site AMH-Gen-II ELISA (n = 62). Wilcoxon signed rank test: p < 0.00001. b: Box plots illustrating the distribution of AMH
levels in women with AMH measurements prepartum and postpartum assessed using the Beckman Coulter Gen II assay (n = 62). Wilcoxon signed
rank test: p < 0.00001
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confirmed by the modified assay. The overall difference be-
tween the values remained higher with the modified assay
for both pre- and postpartal determinations. Furthermore,
our results indicate that the differences between the con-
ventional and modified assay are not independent of the
magnitude of the AMH values in advanced stages of preg-
nancy as well as during the first four days postpartum.
Thus, the decline in AMH levels during pregnancy is ex-
pected to be more pronounced using the modified assay, as
high AMH levels in the early stages of pregnancy would be
more affected by the induced AMH increase.
We have hypothesized [5] that the hypogonadotropic
status may be responsible for the AMH decline. Recently
published data demonstrated that in hypogonadotropic
amenorrhoea AMH levels were not decreased [19]. An-
other study has examined the relationship between
AMH, gonadotropins, estradiol and progesterone in the
first and second trimester and did not found associations
[20]. Therefore, it may be possible that additional factors (e.g.,
the FSH-antagonist follistatin or products of the placenta
which are increasing during pregnancy [21]) are contributing
to the pregnancy-associated and reversible AMH-decline.
Recently published studies showed meaningful AMH
fluctuations depending on storage time at room
temperature with an increase in values after 8 h [11].
The management of our processing procedure of sam-
ples was very strict with a storage time at room
temperature of less than 4 h and storage at −80 °C im-
mediately after processing. None of the samples was fro-
zen twice or more. Therefore, the strict management of
sample handling and storage conditions may have con-
tributed to the consistent results of the two assays. The
storage times at −80 °C for samples of the longitudinal
measured patients varied between 10 and nearly 20 years
before AMH was determined using the conventional
assay in 2011/2012 and using the modified assay in
Fig. 2 a: Bland–Altman plots (incl. mean differences and 95 % limits of agreement) to illustrate differences in AMH between the conventional
and the modified assay (N = 62). Scatter plots including linear regression lines and lines of equality illustrate the difference between values
determined with both assays pre- and postpartum. b: Bland–Altman plots (incl. mean differences and 95 % limits of agreement) to illustrate
differences in prepartal AMH levels between the conventional and the modified assay (N = 62). Scatter plots including linear regression lines and
lines of equality illustrate the prepartum difference between values determined with both assays. c: Bland–Altman plots (incl. mean differences
and 95 % limits of agreement) to illustrate differences in postpartal AMH levels between the conventional and the modified assay (N = 62). Scatter
plots including linear regression lines and lines of equality illustrate the postpartum difference between values determined with both assays
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2014, respectively. This has to be mentioned together
with the small sample size of 11 patients as limitations
of our longitudinal study. Storage-dependent fluctua-
tions of AMH have not been investigated so far for
storage-times of more than 30 weeks [11]. Thus, we can-
not rule out that storage time and conditions had an im-
pact on our results. Our study design was not suitable to
clarify the storage-dependent variance, however, we did
not observe any indication of storage-dependent differ-
ences in the tendency of AMH declining during
pregnancy.
In contrast, the tendency of AMH levels determined with
the conventional and the modified assay was comparable
with the decline in pregnancy as well as postpartum.
In addition, a dilution step to eliminate the comple-
ment (AMH Gen II Assay Buffer (A56021)) is part of
the modified assay but not of the conventional assay
method. To ensure comparability of our results to those
of further studies we strictly followed the manufacturer’s
instructions in performing both assays which included
methods of the respective dilution procedure. However,
investigating the exact differences between the applied
methods was not the aim of the study, but rather to
show that the decline of AMH levels in pregnancy as
well as postpartum was present irrespective of the assays
applied for AMH determination and the preanalytical
step for complement removal. However, new commer-
cially available assays may be able to further improve
AMH assessment in the future.
Conclusion
Since complement is activated in pregnancy, an artificial
decline of AMH during the course of pregnancy could not
be ruled out when determination was done with the con-
ventional assay as recently published by us.
This study using the modified new Beckman Coulter
AMH Gen II Assay which removed the potentially assay-
interfering complement verified the AMH decline during
the course of pregnancy and early after delivery. According
to our data, the AMH decline in pregnancy was not
artificial.
Fig. 3 a: Longitudinal measurement of AMH levels determined with the conventional assay. b: Longitudinal measurement of AMH levels
determined with the modified assay
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